SK66798A3 - Quinoline derivative, preparation method thereof, pharmaceutical composition containing the same and its use - Google Patents

Quinoline derivative, preparation method thereof, pharmaceutical composition containing the same and its use Download PDF

Info

Publication number
SK66798A3
SK66798A3 SK667-98A SK66798A SK66798A3 SK 66798 A3 SK66798 A3 SK 66798A3 SK 66798 A SK66798 A SK 66798A SK 66798 A3 SK66798 A3 SK 66798A3
Authority
SK
Slovakia
Prior art keywords
ethylbenzyl
carboxamide
phenylquinoline
alkyl
formula
Prior art date
Application number
SK667-98A
Other languages
English (en)
Slovak (sk)
Inventor
Giuseppe A M Giardina
Mario Grugni
Luca F Raveglia
Carlo Farina
Original Assignee
Smithkline Beecham Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI952461 external-priority patent/IT1276170B1/it
Priority claimed from ITMI961689 external-priority patent/IT1307331B1/it
Application filed by Smithkline Beecham Spa filed Critical Smithkline Beecham Spa
Publication of SK66798A3 publication Critical patent/SK66798A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK667-98A 1995-11-24 1996-11-22 Quinoline derivative, preparation method thereof, pharmaceutical composition containing the same and its use SK66798A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI952461 IT1276170B1 (it) 1995-11-24 1995-11-24 Derivati chinolinici
ITMI961689 IT1307331B1 (it) 1996-08-02 1996-08-02 Derivati chinolinici
PCT/EP1996/005203 WO1997021680A1 (en) 1995-11-24 1996-11-22 Quinoline derivatives

Publications (1)

Publication Number Publication Date
SK66798A3 true SK66798A3 (en) 1999-01-11

Family

ID=26331326

Family Applications (1)

Application Number Title Priority Date Filing Date
SK667-98A SK66798A3 (en) 1995-11-24 1996-11-22 Quinoline derivative, preparation method thereof, pharmaceutical composition containing the same and its use

Country Status (26)

Country Link
US (1) US6277862B1 (xx)
EP (1) EP0876347B1 (xx)
JP (1) JP2000501104A (xx)
KR (1) KR19990071597A (xx)
CN (1) CN1207730A (xx)
AP (1) AP9801237A0 (xx)
AR (1) AR004972A1 (xx)
AT (1) ATE289994T1 (xx)
BG (1) BG102558A (xx)
BR (1) BR9611820A (xx)
CA (1) CA2238298A1 (xx)
CZ (1) CZ157998A3 (xx)
DE (1) DE69634416T2 (xx)
EA (1) EA002124B1 (xx)
ES (1) ES2236757T3 (xx)
IL (1) IL124522A0 (xx)
MX (1) MX9804107A (xx)
NO (1) NO311212B1 (xx)
NZ (1) NZ323387A (xx)
OA (1) OA11010A (xx)
PL (1) PL326967A1 (xx)
SK (1) SK66798A3 (xx)
TR (1) TR199800924T2 (xx)
TW (1) TW353066B (xx)
UY (1) UY24733A1 (xx)
WO (1) WO1997021680A1 (xx)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU219131B (hu) * 1991-10-18 2001-02-28 Monsanto Co. Módszer és fungicid készítmény növények torsgombabetegségének gátlására és a hatóanyagok
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
GB9825554D0 (en) * 1998-11-20 1999-01-13 Smithkline Beecham Spa Novel Compounds
US7037922B1 (en) 2000-03-10 2006-05-02 Neurogen Corporation Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
JP2002540203A (ja) 1999-03-29 2002-11-26 ニューロゲン コーポレイション Ｎｋ−３および／またはｇａｂａ（ａ）受容体リガンドとしての４−置換キノリン誘導体
WO2000064877A1 (en) 1999-04-26 2000-11-02 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
DE60209362T2 (de) * 2001-04-11 2006-10-26 Glaxosmithkline S.P.A. 3-substituierte chinolin-4-carbonsäureamidderivate als nk-3- und nk-2-rezeptorantagonisten
WO2002089802A2 (en) * 2001-05-08 2002-11-14 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ES2350123T3 (es) 2003-01-28 2011-01-18 Ironwood Pharmaceuticals, Inc. Composiciones para el tratamiento de trastornos gastrointestinales.
GB0303086D0 (en) 2003-02-11 2003-03-19 Merck Sharp & Dohme New compounds
GB0419192D0 (en) 2004-08-27 2004-09-29 Merck Sharp & Dohme Therapeutic agents
US20070249670A1 (en) * 2004-11-09 2007-10-25 Smithkline Beecham Corporation Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof
GB0425077D0 (en) * 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0515580D0 (en) 2005-07-29 2005-09-07 Merck Sharp & Dohme Therapeutic compounds
CN101282961A (zh) * 2005-08-11 2008-10-08 阿斯利康(瑞典)有限公司 作为nk3受体调节剂的烷基吡啶基喹啉
AR057130A1 (es) 2005-09-21 2007-11-14 Astrazeneca Ab Quinolinas de alquilsulfoxido y una composicion farmaceutica
TW200804288A (en) 2005-12-12 2008-01-16 Astrazeneca Ab Alkylsulphonamide quinolines
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
CN101932557A (zh) * 2007-09-28 2010-12-29 葛兰素史密丝克莱恩有限责任公司 糖原磷酸化酶抑制剂化合物及其药物组合物
EA201000392A1 (ru) * 2007-09-28 2010-10-29 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2010078449A2 (en) 2008-12-31 2010-07-08 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2887964B1 (en) 2012-08-21 2019-07-03 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
SI2983667T1 (sl) 2013-04-12 2019-09-30 Ardelyx, Inc. Spojine za vezavo NHE3 in metode za zaviranje transporta fosfata
CA2909752A1 (en) 2013-04-19 2014-10-23 Astrazeneca Ab A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
WO2017072629A1 (en) 2015-10-29 2017-05-04 Cadila Healthcare Limited Pharmaceutical combination of nk3 receptor antagonist and biguanides
JP7292207B2 (ja) 2017-01-09 2023-06-16 アルデリックス， インコーポレイテッド 消化管障害を処置するために有用な化合物
CA3049679A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Inhibitors of nhe-mediated antiport

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2538388B1 (fr) * 1982-12-24 1985-06-21 Pharmuka Lab Nouveaux derives de naphtalene- ou azanaphtalenecarboxamide, leurs procedes de preparation et leur utilisation comme medicaments
JPS6399057A (ja) * 1986-06-27 1988-04-30 Nippon Shinyaku Co Ltd グリシン誘導体
ES2227769T3 (es) * 1994-05-27 2005-04-01 Glaxosmithkline S.P.A. Derivados de quinolina como antagonistas del receptor nk3 de taquiquinina.
IT1270615B (it) * 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina

Also Published As

Publication number Publication date
OA11010A (en) 2003-03-06
US6277862B1 (en) 2001-08-21
MX9804107A (es) 1998-09-30
EP0876347B1 (en) 2005-03-02
AP9801237A0 (en) 1998-06-30
EA199800477A1 (ru) 1998-12-24
TR199800924T2 (xx) 1998-08-21
CN1207730A (zh) 1999-02-10
DE69634416D1 (de) 2005-04-07
EA002124B1 (ru) 2001-12-24
NO982331L (no) 1998-07-22
IL124522A0 (en) 1998-12-06
CA2238298A1 (en) 1997-06-19
TW353066B (en) 1999-02-21
PL326967A1 (en) 1998-11-09
BG102558A (bg) 1999-03-31
JP2000501104A (ja) 2000-02-02
EP0876347A1 (en) 1998-11-11
KR19990071597A (ko) 1999-09-27
AR004972A1 (es) 1999-04-07
DE69634416T2 (de) 2005-12-29
NZ323387A (en) 2000-02-28
NO982331D0 (no) 1998-05-22
CZ157998A3 (cs) 1998-12-16
ES2236757T3 (es) 2005-07-16
BR9611820A (pt) 1999-07-13
NO311212B1 (no) 2001-10-29
WO1997021680A1 (en) 1997-06-19
UY24733A1 (es) 2001-08-27
ATE289994T1 (de) 2005-03-15

Similar Documents

Publication Publication Date Title
SK66798A3 (en) Quinoline derivative, preparation method thereof, pharmaceutical composition containing the same and its use
SK66898A3 (en) Quinoline-4-carboxamide derivatives, their preparation and their use
WO1997021680A9 (en) Quinoline derivatives
EP0804419B1 (en) Quinoline derivatives as tachykinin nk 3 receptor antagonists
EP0874827B1 (en) Quinoline derivatives as nk3 antagonists
ES2201509T3 (es) Derivados de quinolina-4-carboxamida como antagonista de los receptores nk-2 y nk-3.
ES2254688T3 (es) Derivados de quinolina-4-carboxamida como antagonistas de los receptores nk-3 y nk-2.
EP1131294B1 (en) Quinoline derivatives as nk-2 and nk-3 receptor ligands
JP2004517062A (ja) Ｎｋ−３およびｎｋ−２アンタゴニストとしてのキノリン誘導体
AU757836B2 (en) Quinoline derivatives
AU1031797A (en) Quinoline derivatives
NZ500371A (en) NK-2/NK-3 antagonists and their use in treating respiratory disease
AU4263200A (en) Quinoline-4-carboxamide derivatives, their preparation and their use as neurokinin 3 (NK-3)- and neurokinin 2 (NK-2) receptor antagonists
Luca et al. PCT WORLD) INTELLECTUAL PROPERTY ORGANIZATION
CZ416199A3 (cs) Chinolin-4-karboxamidové deriváty jako antagonisté receptoru pro NK-2 a NK-3
KR20010012823A (ko) Ｎｋ-2 및 ｎｋ-3 수용체 길항제로서의퀴놀린-4-카르복스아미드 유도체
ITMI972352A1 (it) Derivati chinolinici, procedimento per la loro preparazione e uso come antagonisti del recettore nk3